Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice

NCT04094051 | Unknown

• 1 other identifier: JNJ-54179060
• Study Type: observational
• Target: 580
• Locations: 1 country
• Sites: 1

Brief Summary

This is a non-interventional, Phase 4 study designed to improve understanding of current clinical practice in the treatment of CLL/SLL and to describe treatment pattern and evaluate outcomes of ibrutinib-treated CLL patients in China. This study will include both retrospective and prospective data collection.

Conditions

Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma

Outcome Measures

Primary Outcomes (2)

• Patient and disease characteristics

  age, gender, Eastern Cooperative Oncology Group (ECOG), stage, Bulky disease, Cytogenetics, median ANC, median hemoglobin, median platelets, comorbidity.

  Up to 10 years

• Treatment pattern

  number of prior therapies, every treatment regimen, dose, cycle/treatment duration, stem cell therapy (SCT), progression-free survival (PFS), overall survival (OS), patient-reported outcome.

  Baseline

Secondary Outcomes (1)

• Treatment response

  Up to 10 years

Interventions

Ibrutinib DRUG

In the retrospective period, clinical information of approximate 500 patients with CLL/SLL prior to the study initiation will be collected retrospectively through chart review. There will be one time follow-up to collect data on disease progression, survival status and patient-reported outcomes.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Retrospective group: CLL/SLL patients who received CLL/SLL treatment before study initiation as judged by participating site physician. A telephone follow-up will be arranged at the time of study initiation to determine the disease progression, survival status, PRO assessments and ADR. If the patient is accessible, oral consent will be obtained and documented in the medical record before the retrospective data collection through chart review. If the patient is not accessible at the time of study initiation, ICF waiver approved by the IRB will be in place for the etrospective data collection according to the latest local regulation. Prospective group: CLL/SLL patients who are on ibrutinib treatment at the time of study initiation as judged by participating site physician or start ibrutinib treatment after study initiation. This group of patients can be divided into two subgroups.

You may qualify if:

• In the retrospective part:
• Male or female patients above 18 years old
• Patients underwent CLL treatment after Jan 1st, 2013
• Patient understand and voluntarily sign an ICF, if applicable.
• In the prospective part:
• Male or female patients above 18 years old
• Patients diagnosed with CLL，including treatment- naïve patients or patients who have received ≤3 prior therapies
• Patients treated with ibrutinib as monotherapy or a part of combination therapy
• Patient understand and voluntarily sign an ICF.

You may not qualify if:

• In the retrospective part:
• Patients with documented diagnosis of other cancers prior to the diagnosis of CLL
• Patients enrolled in interventional clinical trials of any drug for CLL treatment
• In the prospective part:
• Patients with documented diagnosis of other cancers prior to the diagnosis of CLL
• Patients with contraindication listed in the package insert of ibrutinib
• Patients enrolled in interventional clinical trials of ibrutinib or any other drug for CLL treatment
• Patient received Ibrutinib treatment as maintenance therapy.

Sponsors & Collaborators

• The First Affiliated Hospital with Nanjing Medical University: lead
• Xian-Janssen Pharmaceutical Ltd.: collaborator

Study Sites (1)

the First Affiliated Hospital of Nanjing Medical University

Nanjing, Jiangsu, 210000, China

RECRUITING

MeSH Terms

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

ibrutinib

Condition Hierarchy (Ancestors)

Leukemia, B-Cell; Leukemia, Lymphoid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Jianyong Li, Ph.D.

CONTACT

025-83718836; lijianyonglm@126.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Target Duration: 10 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 15, 2019
• First Posted: September 18, 2019
• Study Start: October 1, 2019
• Primary Completion: December 31, 2020
• Study Completion: December 31, 2021
• Last Updated: September 18, 2019

Record last verified: 2019-09

Locations

CN (1)